SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma rises on divesting step-down subsidiary to Eris Pharma

10 Apr 2015 Evaluate

Aurobindo Pharma is currently trading at Rs. 1332.05, up by 7.55 points or 0.57% from its previous closing of Rs. 1324.50 on the BSE.

The scrip opened at Rs. 1328.70 and has touched a high and low of Rs. 1347.00 and Rs. 1314.10 respectively. So far 78519 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1382.25 on 08-Apr-2015 and a 52 week low of Rs. 528.00 on 17-Apr-2014.

Last one week high and low of the scrip stood at Rs. 1382.25 and Rs. 1262.05 respectively. The current market cap of the company is Rs. 39048.25 crore.

The promoters holding in the company stood at 54.06% while Institutions and Non-Institutions held 36.20% and 9.73% respectively.

Aurobindo Pharma has divested its step-down subsidiary, Aurobindo Pharma (Australia) to Eris Pharma Australia. The pharma major will however under an agreement continue to manufacture and supply the products to Eris Pharma for Australian and New Zealand market over next few years.

This divestment is in line with Aurobindo’s strategy of focusing on US, EU and Key Emerging Markets. This subsidiary was not contributing any profit to the company.

Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.

Aurobindo Pharma Share Price

1435.90 15.00 (1.06%)
23-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1679.85
Dr. Reddys Lab 1333.05
Cipla 1305.85
Zydus Lifesciences 947.10
Lupin 2340.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×